Creating a Cancer-Free World:
The New James Cancer Hospital and Solove Research Institute

Cancer is the world’s leading killer, claiming more lives than any other disease, act of violence, addiction, war or natural disaster. One in two men and one in three women will be diagnosed with cancer in their lifetime. And fighting this disease costs our nation more than $338 billion annually in medical expenses and lost productivity.

While discoveries and progress are made every day, demand for cancer services is expected to strain hospitals, with cancer rates in the United States increasing more than 45 percent by 2030. Closer to home, our own state will face challenges for expanded cancer prevention and care as incidents will increase by 20 percent over the next several years. And, today, the James Cancer Hospital and Solove Research Institute is beyond capacity for inpatient and many outpatient services.

But there is great hope rising...literally.

We have forged a new vision and designed a bold new environment that leverages the depth and breadth of the nation’s largest public university to create the highest standards for the prevention, detection, treatment and cure of cancer.

The new James will stand as a transformational facility, one that inspires and enhances collaboration among a wide variety of people and disciplines — the type of collaboration that is demanded when curing one of the world’s most complex diseases. It will stand as a beacon to attract and retain the world’s leading research experts, the most inquiring young minds and best physicians to one place, at one time — at Ohio State. It will be where we revolutionize the way cancer prevention and care is provided by predicting not just the treatments needed to win the cancer battle, but also by determining those at highest risk and pre-empting cancer from striking in the first place.

The new James Cancer Hospital and Solove Research Institute will be where we create a cancer-free world.
CREATING A CANCER-FREE WORLD:

The New James Cancer Hospital
and Solove Research Institute

- The new building will be one of the largest cancer hospitals in the world and will further the Ohio State tradition of bold discovery, transformation and improving the care for those in our community and around the world.

- The expansion will help Ohio State attract and retain top doctors and scientists, as well as compete for funding from the National Institutes of Health, National Cancer Institute and other sources — all of which contribute to excellence in patient care.

- Patient floors integrate space for cancer care, research and team collaboration, placing clinicians and researchers in close working proximity so they can more readily translate scientific discoveries into innovative care for patients.

- This facility will house one of the country's few above-ground radiation oncology units, an environment designed to ease stress and enhance healing by offering patients natural light and outside views during their treatment.

- Patient-friendly concourses and inviting lobbies link laboratories, patient rooms, offices and garages, giving patients and visitors convenient access to all healthcare services at the OSUCCC – James.

- Each private patient room will allow patients to receive nearly all of their care in the comfort of their own rooms with their family at their side.

- The new hospital is LEED-certified, meaning it will use 20 percent less energy than other facilities its size.

The New James Cancer Hospital
and Solove Research Institute
By-the-numbers

- 21 percent: Expected increase in admissions over the next 10 years

- Nearly 300: Private cancer patient rooms

- 21: Levels in the new building

- 1 million: Square feet in the new building

- 1 hour: Flight time to the new James for more than half of the U.S. population

- 256 feet: Height of the new building from the ground floor to the roof, which will make it the 23rd tallest healthcare facility in the world

- 14: Operating Rooms

- 40: Chemotherapy Stations

- 20,000: Square feet of research space within the new building

- 16: Infusion rooms on the clinical treatment unit for patients receiving infusion therapies

- $1.7 billion: The economic impact of Ohio State’s Wexner Medical Center expansion, including the new James Cancer Hospital and Solove Research Institute
The Dedication of the
new James Cancer Hospital
and Solove Research Institute
Friday, November 7, 2014
Welcome

Welcome to the new Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, a towering structure whose completion will mark the end of The Ohio State University’s largest ever-construction project and the beginning of a new era in science-based cancer care.

On December 12, patients will begin moving into our 21-floor, 1.1-million-square-foot, 306-bed cancer hospital. The new James will officially open December 15 as a transformational facility that is designed to integrate scientific research, education and innovative patient care more closely than ever before, strengthening our ceaseless pursuit of a cancer-free world.

By placing our world-class researchers and clinical subspecialists in closer working proximity, the new James will help these experts more readily share ideas and discoveries leading to precisely targeted treatments for each patient’s biologically unique cancer. Undoubtedly, their daily interaction within these walls will lead to breakthroughs and potential cures that will have worldwide benefit while elevating the global reputation of both The Ohio State University and Ohio State’s Wexner Medical Center.

And all of you have helped bring this about. The new James is a triumph not only for all who will work, volunteer and be treated here, but also for everyone in our community whose generous support has made it possible. Every cancer discovery, treatment, cure and prevention strategy that will originate here can be attributed in part to the many donors who have helped finance this magnificent building.

When the original James was under construction in the 1980s, its namesake, the late Arthur G. James, MD, rightly observed that “a new day is coming.” And now, another new day dawns. We are grateful to you for hastening its arrival.

Michael A. Caligiuri, MD
Director, The Ohio State University Comprehensive Cancer Center
CEO, James Cancer Hospital and Solove Research Institute

Steven G. Gabbe, MD
Senior Vice President for Health Sciences,
The Ohio State University
Chief Executive Officer, The Ohio State University Wexner Medical Center
Afternoon Program
The New James Cancer Hospital and Solove Research Institute
Dedication Ceremony

November 7, 2014
2:00 p.m.

Michael V. Drake, MD
President, The Ohio State University

The Honorable Sherrod Brown
United States Senator

The Honorable Michael B. Coleman
Mayor, City of Columbus

Chancellor John Carey
Ohio Board of Regents

Steven G. Gabbe, MD
Senior Vice President for Health Sciences, The Ohio State University
Chief Executive Officer, The Ohio State University Wexner Medical Center

Michael A. Caligiuri, MD
Director, The Ohio State University Comprehensive Cancer Center
CEO, James Cancer Hospital and Solove Research Institute

Ribbon Ceremony
Pedestal Moments

Bonita Griffin
Shannon Peterson
William Farrar, MD
Arthur James
Mike Ostrowski, PhD
Cindy Hilsheimer
Judy Jefferson-Gordon
Bob Masie
Maddie Spielman
Abigail and Les Wexner
Doug Ulman

Additional community members will join
our pedestal speakers in the ribbon ceremony.

Please join us for a tour of the new hospital
immediately following the ceremony.

The new James Cancer Hospital and Solove Research Institute

Key Stats
3rd-largest cancer hospital
in the nation

21 floors

1.1 Million square feet

306 inpatient beds,
including

36-bed BMT unit

14 Operating Rooms

6 Interventional Radiology Suites

7 Linear accelerators
for radiation therapy

Dedicated Early-Phase Clinical Trials Unit
Philanthropic Support

Without philanthropic support, this transformational facility would not be possible. The new James is a triumph not only for all who will work, volunteer and be treated here, but for everyone in our community whose generous support has made it possible. Thank you.

American Electric Power
American Floor Source
Anchor Housing Corporation
Ellen and Jim Buehnmann
Janet and Bob Johnson
Baker & Hostetler
Linda and Don Barger
Anne and Gales Barnes
Battelle
Jenni and Davis Belford
Donna and Darrel Benhase
Michael Bloch
Joni Block
Teni and Jeff Block
Jeri Block and Lobby Schottenstein
Shirley and Mary Block
Bob Evans Farms, Inc.
Frances Bullock
Ron Brooks
Delaney and Stuart Burgooner
Cardinal Health
Celebration for Life
The Cossman Team
Chemical Abstracts Service
Michelle and Andy Corbin
Betty and Lewis Cohen
Contract Lumber
Joy and Sue Coughlin
Joy Coughlin, Jr.
Diana and John Coughlin
Kris and Mike Coughlin
Julie and Troy Coughlin
Georgia and John Dallaire
Janice and Dale Darnell
Lyndal M. and Steven A. Davis
Betsy and Rolando DeAquino
Sharon and Mike DeAcutis
Jane and Walt Dennis
Jill and Chris Doody
Brian Doyle
EMH&TE
Easton Community Foundation
FloAnn and C. John Easton
Gail Ferber
First Third Bank
Karen and Michael Fiorito
Linda Schottenstein Fisher
Patricia and Steven Gabbe
Eilde and Donald Gutshoven
Pam Garvin
Janice and Michael Gasser
Gerber Snell/Weinberger
Alejandra and Jay Gerlach
Libby and Rick Germain
Joyce and Russ Gertmenian
Julie Block Glassman and Andy Glassman
Glitzer Realty Trust
DeeDee and Herb Glitzer
Greif Inc.

Thomas R. Gross, Jr.
Hadler Companies
Joyce and Michael Hallet
Ellie and William Hallett
Hamilton Parker Company
Ellen and Mark Hardyson
Harold C. Schott Foundation
Herbert J. Block Memorial Tournament
Irene Levine and Lee Hess
Cindy and Larry Hibbett
Hinson Family Trust
Char Hinson
Lisa and Alan Hinson
HOK
Adam Holdeman
Robin V Holdeman
Celeste Hoisieh
Susie and Peter Horvath
Kris H and Michael D Hund
1351 Foundation
Marcia and Bill Ingram
Nancy and Cameron James
JECS Foundation
Dorothea and Eric Johnson
Phyllis A Jones
Paty and Jerry Jurgenzen
Family and Friends of Phyllis Kalder
Cari and David Kass
Linda and Frank Kass

Ed Razek
Lori Hinson Rech
Janie Restor
Lyenne and Marty Rodger
Cynthia and James Rodine
Barbara and R. L. Richards
Jim Ricker
Rite Rlg
Joyce and William Roberts
Linda Robins
Courtney Granville and Daniel Rosenthal
Ellen and Alan Rudy
Brooke and Charles Ruma
Russilli Construction Co., Inc.
Ellen and Dave Ryan
Safe Auto Insurance Company
Peggy and Richard Santulli
Sasaki
Saul Schottenstein Foundation
M.J. and Ronald Schnipke
Kathleen and Michael Schoen
Schottenstein Stores Corporation
Carole and David Schuller, MD
Scotts Miracle-Gro
Pamela and Ira Sharfin
Davina and Simeak Shawpin
Tina and George Skeston
Stuart Sloan
Judy Smith and Michael T. Thomas
Lee M. Smith & Associates Co LPA
Smart Construction
Liz and John Sokol
LaDonna Solove

Chris Spielman
Pat and Yoram Stein
Patti and Steve Steinour
Cathy Tadb
Judy and Michael Thomas
Ellen and Jim Tressell
Barbara Trueman
Connie and Craig Tuckerman
Judy and Steve Tuckerman
Turner Construction Company
Sharon and Charles Turney
Trevor Brands
Up on the Roof
Vorys Sater, Seymour & Pease
W.W. Williams Co.
Seanna and Matt Walter
Margaret and Robert Walter
Angie and Donald Ward
Carol and David Wasi
Wasserman Company
Beatrice and Alan Weiler
Mazy and Bob Weiler
Artino and Michael Weiss
Abeil and Les Wexner
White Castle
Carolyn and Lance White
Kathy and Alex Whitehouse
Mincha and Monty Will
William Randolph Hearst Foundation
Ann and John E Wolfe
Jan Minton Woods
Vonrly Plumbing Supply
Kathy and Jay Worby

donors listed represent gifts of $25,000 or more
## Innovative Design That Provides a State-of-the-Art, Healing Environment

- Multidisciplinary teams of oncologists, surgeons, nurses and pharmacists who sub-specialize in specific cancers and deliver the most advanced treatments
- Translational research labs on each inpatient floor that bring physicians and researchers together to develop and deliver the most effective targeted treatments for patients
- Cancer Clinical Trials Unit experienced in conducting safe, innovative early-phase trials
- One of the nation’s largest Blood and Marrow Transplant Units supported by a state-of-the-art cellular processing lab
- Advanced genomic technologies to identify both the molecular changes causing a patient’s cancer and the right drugs to treat it

## The New James
### Patient Room Features
- Every patient room is private
- Identical room layouts to improve patient safety
- Ample space for family and visitors
- State-of-the-art technology for patient care and entertainment
- Large windows and an abundance of natural light
- Personalized nutrition through dining-on-demand services
- Expansive views and nearby access to green spaces
- Additional features for visitors on every floor: lounges, private consultation rooms, Wi-Fi capabilities, TVs, computer terminals and respite areas

## The New James
### By the Numbers
**Third largest cancer hospital in the nation**
- 21 floors
- 1.1 million square feet
- 306 inpatient beds, including a 36-bed Blood and Marrow Transplant unit
- 14 operating rooms
- 6 interventional radiology suites
- 7 linear accelerators for radiation therapy

Dedicated early-phase clinical trials unit
INTEGRATIVE THERAPY PROGRAM

URBAN ZEN

Designed for patients, families and staff incorporating three complementary healing methods:

🌟 Yoga Therapy
🌟 Reiki
🌟 Essential Oil Therapy

Supported by Ohio State’s evidence-based research, these therapies have shown they contribute to patients’ healing and recovery.

Provides relaxation and comfort
Reduces pain, anxiety, nausea and insomnia.
What is Urban Zen?
Urban Zen is a program inspired by fashion designer Donna Karan, whose husband died of cancer, designed to integrate Eastern healing techniques with Western medicine to provide the very best outcomes for people with a variety of illnesses and injuries. Urban Zen is uniquely designed to relieve the classic symptoms of illness:
- Pain
- Anxiety
- Nausea
- Insomnia
- Constipation
- Exhaustion
- Sadness

Ohio State's Integrative Therapy Urban Zen program incorporates three complementary therapies:
- Yoga
- Reiki (hands-on healing)
- Essential Oil Therapy

Urban Zen addresses the emotional and spiritual well-being not only of our patients—but also addresses the needs of our patients' families and caregivers. Supported by Ohio State's evidence-based research, these therapies have been shown to contribute to healing and recovery.

What kind of training do Urban Zen providers at Ohio State have?
The majority of our providers are nurses who have spent at least one year training and practicing Urban Zen therapies. The training program requires more than 11 full days of training plus an additional 50 supervised clinical hours in an approved healthcare facility. Our nurses have taken this rigorous training program on their own time because they are committed to providing our patients with the very best experience and outcomes possible.

How can a patient receive these therapies?
Urban Zen therapies can be requested by nurses, physicians, and other care providers, as well as patients and family and are documented in the patient chart. These therapies are funded by the Medical Center and philanthropic support so that they can be offered to our patients and families at no charge.

For more information about the program, training or to donate, please email urbanzen@osumc.edu.
We've been waiting ten years to invite you to this...

The New James Cancer Hospital and Solove Research Institute | Opening December 2014

<table>
<thead>
<tr>
<th>Event Type</th>
<th>Date</th>
<th>Time</th>
<th>Details and Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Faculty/Staff Open House</td>
<td>Wednesday, November 5</td>
<td>6 – 8 a.m.</td>
<td>11 a.m. – 2 p.m.</td>
</tr>
<tr>
<td>Premier Fundraising Event</td>
<td>Thursday, November 6</td>
<td>6:30 – 9:30 p.m.</td>
<td>For more information, contact the Development Events Office at 614-293-4700.</td>
</tr>
<tr>
<td>Dedication Ceremony</td>
<td>Friday, November 7</td>
<td>By invitation only. 2 – 4:30 p.m.</td>
<td>This event will be webcast. Viewing locations will be announced at a later date.</td>
</tr>
<tr>
<td>Referring Physician Reception</td>
<td>Friday, November 7</td>
<td>By invitation only. 5:30 – 7:30 p.m.</td>
<td></td>
</tr>
<tr>
<td>James Ambassadors Society Celebration</td>
<td>Sunday, November 9</td>
<td>11:30 a.m. – 1 p.m.</td>
<td>460 W. 10th Ave. Columbus, Ohio 43210 Free admission and parking. For more information, visit go.osu.edu/NewJames.</td>
</tr>
</tbody>
</table>
New James Cancer Hospital a ‘beacon of hope’
Researchers and physicians will rub elbows in OSU’s new $705 million facility, promoting advanced treatment and collaboration that could lead to a cure

The light-filled atrium in the new James Cancer Hospital and Solove Research Institute.

By Ben Sutherly
The Columbus Dispatch • Friday November 7, 2014 9:24 AM
Comments: 2 150 12 310

Caring for cancer patients and, perhaps one day, contributing to cures — both under one roof.

That will be the goal when 200 patients move into the new Arthur G. James Cancer Hospital next month. In some cases, Ohio State University’s scientific quest for cures and better treatments will go on right down the hall from inpatient rooms.

Such proximity matters, said OSU molecular biologist Denis Guttridge, whose lab is seeking to demystify muscle-wasting malignancies such as those that afflicted Steve Jobs and Patrick Swayze, both of whom died of pancreatic cancer. Tissue quickly breaks down after it’s collected. By moving processing centers closer to patients, more of that tissue can be saved, strengthening the data that scientists need for their work, Guttridge said.

More cancer patients should mean more enrollees in clinical trials, which in turn could hasten scientific discoveries. And within what Ohio State bills as the nation’s third-largest cancer hospital, researchers will cross paths more often with doctors and other clinicians — chance encounters that sometimes prove to be serendipitous, they say.

“This is what you want in an academic center of excellence,” said Guttridge, who has worked at Ohio State for 13 years.
Dr. Raphael Pollock, the hospital's chief of surgical services, agrees. "It's going to bring ... the laboratory bench and the bedside closer and closer together. That's how (patients) are going to get access to the very best cutting-edge treatments," said Pollock, a recent recruit from MD Anderson Cancer Center at the University of Texas in Houston.

The new hospital, to be dedicated today and open to the public for tours from 1 to 4 p.m. on Sunday, is four times larger than the current James hospital.

It will give all OSU cancer inpatients private rooms for the first time. (Some patients in the soon-to-be-vacated James shared a room with another patient.) The tallest building on campus at 297 feet, the new hospital reflects the university's ambitions to become a household name in cancer care, mentioned in the same breath as the nation's most elite cancer institutions. "It really makes a statement about Ohio State's commitment to curing cancer," said Dr. Michael Caligiuri, the CEO of the James.

It's not unusual for cancer centers to house researchers and clinicians together, said Barbara Duffy Stewart, executive director of the Association of American Cancer Institutes.

But bringing patients into that same environment, as the new James hospital will do?

"It's rather new to have that mix," she said.

Much like its future patients, the new James hospital has had quite a journey. And its prognosis at times seemed grim.

Conceived more than a decade ago, the $705 million hospital survived infighting between cancer-hospital donors and past medical-center executives.

When Dr. Steven Gabbe returned to Ohio State in 2008 to be chief executive of its medical center, the hospital was embarking on a redesign of the new James, a change in course that would ultimately lead to a lawsuit by the project's then-architect.

"Mr. (Leslie H.) Wexner (the medical center board's current chairman) charged a group of us with developing a new plan," Gabbe said. "We met 100 times in the next 90 days."

"When we were done, we had a design that really had a lot of input from a lot of people."

A single tower had replaced two planned patient towers, and the new hospital seemed to be a better fit with other buildings on the OSU campus, said Gabbe, describing it as a "beacon of hope."

The new James can't open soon enough for hospital executives. During a recent tour, Caligiuri pulled out his smartphone and showed one reason: In its current 24-year-old home, whose future has not been determined, the James often has no beds available. Officials said the new hospital should be able to comfortably handle the 11,700 admissions expected during the current fiscal year, as well as anticipated annual growth of 4 percent for some time.

Some of the cancer hospital's growing pains have yet to be resolved. Its opening is displacing a significant amount of parking for employees of Ohio State's hospital system, leaving some of them disgruntled. Caligiuri said hospital officials are working through the issue.

The new hospital also symbolizes the outsized impact of the medical center on Ohio State's overall fiscal health. Only four other rated public universities derive a greater percentage of their revenue from patient care, according to Moody's Investors Service. That reliance can bring risks, and the university's financial officials are working to keep a lid on the costs of the new cancer center, which increased the university's overall debt to $2.8 billion.

"That's something we're comfortable managing," said the university's new president, Dr. Michael Drake. He said Ohio State's investments in cancer care are sound and important, bringing to central Ohio what he described as "a world-class facility" that will benefit the entire community.

...
Developers get big ‘no’ from voters
Southwest Licking emergency-operating levy rejected
Gahanna leaders reviewing city tax code after judgment for plaintiffs
District leaders: Graduation testing should not trump instruction time
Initial reports say deadly fire does not appear to be arson
Speed, volume on avenue pose concerns for residents

OSU executives have spared few superlatives in describing the new cancer hospital, even labeling it “the world’s most advanced.”

Asked about the basis for that label, Caligiuri said the new facility, despite being designed years ago, seems well-suited to meet the evolving needs of today’s cancer patients, their caregivers and researchers.

Although consensus about what constitutes the world’s most advanced hospital might be hard to come by, there’s little doubt that the new James has an important role in attracting some of the nation’s top researchers to Columbus, Caligiuri said. He offered as one selling point the location of linear accelerators above-ground so that people receiving radiation treatments can have ready access to natural light. That $100 million federal investment in the hospital has played a role in the recruitment of more than a dozen radiation oncologists in recent years, he said.

“It was very important to me on a personal level,” Pollock, the surgical-services chief, said of the new hospital’s role in his decision to come to Columbus from Texas. The timing of his arrival let him participate in staffing decisions, equipment purchases and other matters that have direct impact on clinical care and research.

Other high-tech highlights of the new hospital include a $7.5 million, 3-Tesla magnetic resonance imaging machine that can make images of patients during surgery. (A Tesla describes the strength of a magnetic field.)

And some memorable aspects of the building are low-tech. Terrace gardens on the 14th floor will grow black raspberries and other foods that are thought to lower the risk of certain cancers, Gabbe said.

The new James has fewer than 10,000 square feet of lab space, and most new research will still happen in nearby buildings. Caligiuri estimates it will take about 60,000 square feet of additional lab space to recruit the 30 or so researchers needed to propel Ohio State into the top-10 cancer programs nationally in terms of National Cancer Institute funding. In 2013, the university ranked 17th in total NCI support, receiving $42.4 million.

Pelotonia, the charity bike ride that benefits the James, is expected to raise more than $20 million this year, money that also helps the hospital recruit top talent, Caligiuri said.

While the new hospital has been an expensive undertaking, the cost of cancer to worker productivity and society as a whole can’t be overlooked, he said. According to the university, the nationwide direct medical costs of cancer exceed $89 billion annually.

"Before we start worrying about whether we can afford this, we need to switch and say, we can’t afford not to do it," Caligiuri said. "And to go all out, make the greatest investment we can to preventing cancer and curing cancer."

bsutherly@dispatch.com
@BenSutherly

WEAKLY ADS

BIG LOTS
Nobody Beats our Price! Brand New

Macy’s
Spectacular Specials Storewide! 4 Days Left

STAPLES
Get your perfect new computer for less than you think Expires Today

COMMENTS
Ohio State’s new James Cancer Hospital won surprising U.S. aid
OSU’s new cancer hospital won federal aid created for another college

By Bill Bush
The Columbus Dispatch • Saturday November 8, 2014 5:29 AM

In December 2009, politically powerful U.S. Sen. Chris Dodd of Connecticut inserted a $100 million “hospital construction grant” into the Affordable Care Act bill, which a Senate committee he headed was helping to write.

Days later, the University of Connecticut was publicly thanking Dodd, as it was one of a handful of hospitals in the nation that qualified to apply for the grant. It was generally understood that Dodd, who was facing a tough reelection campaign that he would withdraw from days later, had inserted the grant for UConn, which was trying to finance the replacement of its hospital.

“We very much appreciate Sen. Dodd’s willingness to offer up this proposal, and we can’t thank him enough for all his hard work on behalf of the state and the University of Connecticut,” UConn President Michael Hogan said days after the grant was inserted.

But another hospital also qualified: Ohio State University’s Wexner Medical Center. It met the criteria of a facility that provides research and inpatient care or outpatient clinical services, and that was affiliated with an academic health center at a public research university “that contains a state’s sole public academic medical and dental school.”

Ohio Sen. Sherrod Brown, who also was on the committee drafting the health-care legislation, phoned OSU officials, hoping that maybe the university could pry

$15 million or so out of the grant that seemed so obviously headed to UConn.

Dodd “wrote it in a way that the University of Connecticut would have the best chance to get it,” Brown said yesterday in an interview at the dedication of OSU’s new Arthur G. James Cancer Hospital.

A year later, in late December 2010, Brown said, he got a call while riding his exercise bike in his home near Cleveland. It was federal Secretary of Health and Human Services Kathleen Sebelius.

“Did we get some part, $10 or $15 million?” Brown asked her.

“No,” Sebelius said.

“Then what are you calling for?” Brown asked.
Because you’re getting the whole $100 million,” Sebelius said.

“I said, ‘I assume this is your second call,’” Brown said, and Sebelius acknowledged that she had just hung up with an upset Dodd.

The language in the law provided for a peer-review process, to let medical professionals rather than politicians guide the grant, and Ohio State’s idea apparently appealed to them: use the money to make radiation therapy for cancer patients less dreary.

Patients “found their treatment depressing,” said Dr. David Schuller, who led the team that wrote the grant application. “Nearly 100 percent of all radiation facilities are in the ground with no access to natural light. It’s easier to provide radiation protection (for workers and others) in a subterranean environment.”

But the new James’ radiation facility is on the second floor of the 21-story building, with sunlit open areas more reminiscent of an upscale hotel lobby than a treatment facility.

In the rooms that house the seven massive linear accelerators, which rotate around patients to precisely shoot radiation into tumors, the floors and ceilings are 6-foot-thick slabs of concrete and steel. The walls are 4 feet thick, and where the radioactive beams hit walls, high-density concrete imported from South Africa was used, said Anthony McCabe, a senior quality and patient-safety manager.

“We’ve got to protect everybody up above, below, inside,” said McCabe, who pushes a button to slide a 20,000-pound door sealing off the room where patients will receive their radiation treatments alone. The door is made of steel, lead and boron. Patients can choose the color of the lighting and listen to music they have selected.

Because the James provides all radiation treatments for Nationwide Children’s Hospital, the unit also has facilities for children, including a waiting room where kids can play with farm animals on an interactive screen that takes up an entire wall.

“After the award was made, the good folks at the University of Connecticut insisted on seeing our application,” Schuller said. “We submitted that to them like cordial colleagues — after our legal counsel had heavily redacted all of any confidential information.”

But Ohio State didn’t hand the application over until the grant money had started flowing into its bank account, Schuller said.

bbush@dispatch.com

@reporterbush
Ohio State cancer center’s former home might house brain, spine hospital

By Ben Sutherly
The Columbus Dispatch • Wednesday January 28, 2015 6:14 AM

The former Arthur G. James Cancer Hospital building would become home to a three-story brain and spine hospital under a proposal to go before Ohio State University trustees this week.

The project’s total budget would be $14.3 million, including $10.9 million for construction. The hospital’s 80 to 90 private inpatient beds would be an increase from the current 60 to 70.

Its specialty-care units would include: cognitive/dementia; trauma of the brain and spinal cord; spine; stroke; neuro-restoration; and acute neuro-rehabilitation.

Patients would stay in private rooms in the new hospital when it opens in 2016. Patients now usually have to share a room.

The new hospital will be key to growing Ohio State’s stroke program, developing its spinal-cord injury and traumatic brain-injury programs and treating patients with Alzheimer’s and Parkinson’s diseases, said Dr. Ali Rezai, director of the university’s neurological institute.

It also would boost faculty members’ research and clinical trials in the neurosciences, he said.

Greater coordination among researchers should result in new neurological therapies that will ultimately be used in community hospitals, Rezai said.

He said he expects that the hospital eventually would add more beds. In 2013, Ohio State officials estimated the new brain and spine hospital would have 100 to 125 beds.
Patients "can increasingly receive multidisciplinary care in a single visit instead of multiple visits," said Amanda Lucas, the institute's executive director.

The university paid consultants $2 million to plan a renovation of the former James hospital building on W. 10th Avenue. The James relocated last month to the university's new, $750 million hospital building.

The neurosciences are among the most profitable of all hospital service lines. OhioHealth's Riverside Methodist Hospital is scheduled to open a $321 million, 10-story neuroscience and cardiovascular tower in July.

Riverside has 114 neuroscience beds, with the expansion expected to result in a net increase of at least 14 neuroscience beds.

Ohio State officials declined to say how the remaining part of the old James hospital would be used. It was built in 1990 and cost more than $61 million.

bsutherly@dispatch.com

@BenSutherly

This Week's Circulars

Comments

Please note: the username, first name and last name associated with your account will appear with your comment on this site.

Comment

Place comment here

Post to Facebook or Twitter

Post

Kay Moon (KAYMOON)

This could be big.
**Location:**
- 300 W. 10th Avenue, Columbus, Ohio 43210
- In The Ohio State University Medical Complex

**Important Facts:**
- Component of The Ohio State University Comprehensive Cancer Center. One of only 28 in the nation designated by National Cancer Institute.
- One of only a handful of free-standing cancer research and treatment facilities in the U.S.
- One of only nine cancer hospitals in the nation to be excepted from Medicare prospective reimbursement (DRG's).

**Facilities:**
- Twelve floors comprising 271,000 square feet.
- 160 patient beds, including 24 bed bone marrow transplantation unit.
- 26 basic research laboratories and support facilities.
- Outpatient facilities including 40 physician examination and consultation rooms.
- Six specialized surgical suites and 8-bed recovery unit.
- Retail pharmacy.
- Dental suites.
- Clinical laboratory.

**Special Features:**
- Three linear accelerators for delivering intense, precisely-focused radiation therapy to deep-seated tumors.
- American Cancer Society Babe Zaharias Women's Cancer Center.
- Ambulatory Surgery Center.
- Intraoperative Radiation Therapy Suite to allow radiation to be delivered during surgery.
- Advanced technologies for better imaging and the earlier diagnosis of cancer.
- Outpatient cystoscopy.
- High Dose Rate Brachytherapy, Hyperthermia, other radiation therapies delivered intraoperatively.
- Cutaneous Oncology & Dermatological Surgery Suite.

**Expected Use:**
- Estimated 4,800 inpatients and up to 100,000 outpatients are expected to be treated annually.

**Research Focus:**
- Basic research into the causes of cancer.
- Development of anti-cancer drugs.
Fact Sheet  Continued

- Improving diagnostic methods.
- Finding better methods of prevention.
- Determining better treatment methods through surgery, chemotherapy, immunotherapy, radiation, and innovative combinations of modalities.

Research Achievements of OSU Cancer Program:

- Discovery of hairy cell leukemia by Dr. Bertha Bouronde.
- Development of deoxycoformycin to treat hairy cell leukemia.
- Pioneering advancements in isotope application, including the development of after-loading techniques for brachytherapy by Dr. William Myers.
- Discovery of effective vaccine for feline leukemia by Dr. Richard Olsen.
- Development by Dr. Charles A. Doan of the concept of hypersplenism and introduction, in collaboration with Dr. Bruce Wiseman, of the supravital staining technique.
- First utilization of brachytherapy at The Ohio State University by Dr. Arthur G. James and Dr. Ulrich Henschke utilizing Cobalt-60 and Gold-198.
- Early work on Boron-Neutron Capture Therapy by Drs. Rolf Barth and Albert Soloway.
- Development of Radioimmunoguided Surgery by Dr. Edward Martin and Professor Marlin Thurston.

Benefits:

- Brings research and treatment under one roof to allow new advances in detection and treatment to be applied more quickly and efficiently for patients.
- Available to the 49,000 Ohioans and others in the Midwest who are diagnosed with cancer each year.
- Larger number of patients makes use of highly sophisticated diagnostic and therapeutic equipment more cost effective.
- Expertise in cancer treatment and research gained by staff is disseminated to medical, nursing, and allied health professionals and students in the University medical center programs.
- Patient receives more comprehensive care in a setting geared solely toward the treatment of cancer.
- Patients are provided with full range of needed emotional, spiritual, and psychological support, along with follow-up and rehabilitative services.

Construction:

Ground breaking—July 10, 1984
Opening—July 9, 1990
Architect—NBBJ (Columbus, Ohio)
Ohio State University part of FDA e-cigarette studies

By Michael Huson

The Columbus Dispatch • Monday August 8, 2016 5:50 AM

Amy Zwarycz smoked her first cigarette lying on the front lawn of her best friend’s house in Houston, Minnesota.

“Hanging out, being young and wanting to try new things, we went to the first thing that seemed normal but was something we knew we should not do,” the 20-year-old said.

Four years later and still smoking as a sophomore at Ohio State University in 2015, Zwarycz’s habit has made her a good candidate for one of two studies examining the health effects of electronic cigarettes and tobacco products. Information from the studies are expected to help the U.S. Food and Drug Administration, which will begin regulating e-cigarettes today.

The two clinical studies at Ohio State University’s Arthur G. James Cancer Hospital are funded by the National Cancer Institute and the FDA.

“The FDA values the research being done to help inform the agency about how best to protect the public health, especially youth, from the death and disease caused by tobacco use, and this includes the work being done by Ohio State University,” said FDA spokesman Michael Felberbaum.

To learn whether e-cigarettes affect lung health differently than cigarettes, researchers are asking non-smokers to use unflavored, nicotine-free e-cigarettes. Samples of lung fluid are collected from them and from tobacco users to compare, said Dr. Peter Shields, deputy director of the OSU Comprehensive Cancer Center and thoracic oncologist with the James.

“Since we all assume that e-cigarettes are less toxic than cigarettes, the question we’re trying to answer is: How much less?” he said.

Researchers are studying the comparative inflammatory responses between the lungs of smokers and nonsmokers, and those using e-cigarettes who inhale vaporized juice containing propylene glycol and glycerin, which are considered safe in foods and cosmetics.

“But we have no idea what happens when these chemicals hit the lungs,” Shields said. “Then, when they get heated, there are breakdown products of those chemicals that are known as being irritants, things that cause inflammation — part of the pathway toward cancer and lung disease.”

Shields also is working with the University of Minnesota and Roswell Park Cancer Institute in Buffalo, New York, to investigate the effects of carcinogens in relation to e-cigarettes and tobacco use of about 600 subjects
The study also aims to collect information concerning whether e-cigarette flavors play a role in influencing the use of those devices.

Zwarycz said she doesn’t have much interest in taking up the e-cigarettes she used in the study, nor does she have plans to stop smoking cigarettes.

“In my head, a big part of quitting is wanting to quit,” she said. “That has yet to come into my mind. I really have no desire or motivation to quit.”

Another study participant, Ryan Billingham, 25, of Columbus said e-cigarettes helped him quit smoking tobacco about a year and a half ago.

“I’m very happy. My lungs feel a lot better. I can breathe,” he said. “Anytime I see someone smoking and they want to quit, it’s the first thing I recommend.”

Shields said e-cigarette research in the United States focuses on studying toxicity, not the devices’ ability to help a person quit smoking.

The pilot study was supported by money raised for cancer research through the Pelotonia cycling event. The event has raised $106 million for the Comprehensive Cancer Center at the James Cancer Hospital and Richard J. Solove Research Institute since 2009, according to Pelotonia.

mhuson@dispatch.com

@Mike_Huson

You May Like

Old Photos That Will Take Your Breath Away
Detonate

29 Warships That Are Changing the Future of Warfar...
Semesterz

Can We Guess Your Education Level?
Topix Offbeat

Your boss will absolutely hate this game!
Stormfull: Free Online Game

Rescuers Thought It's A Dog, But It Isn't
Mental Flare

10 Clothes Middle-Aged Women Should A...
Lifescr ipt
OHIO STATE

Cancer hospital CEO resigns

By JoAnne Viviano The Columbus Dispatch

Ohio State University has announced the resignation of the chief executive officer of the James Cancer Hospital at the university’s Wexner Medical Center.

OSU President Dr. Michael V. Drake announced in a Wednesday message to faculty and staff at the medical center that Dr. Michael Caligiuri had resigned.

The message did not give a reason for the resignation. Caligiuri, 61, of Upper Arlington, will return to his tenured faculty position and serve as special adviser to the president through the remainder of the year to help with a transition process. Caligiuri could not be reached by The Dispatch for comment Wednesday.

The university is appointing Dr. Raphael Pollock as permanent director of the university’s Comprehensive Cancer Center and putting together a transition team for oversight of day-to-day operations at the James, the message says. Pollock had been appointed interim director of the cancer center earlier this month, when Caligiuri stepped down from that position after 14 years.

“Dr. Caligiuri has been an integral part of the success of our cancer program and our efforts to advance the care we provide to patients and their families in our community, across the nation and around the world,” the message says. “The university is thankful for his many years of dedicated service and leadership — as are the countless individuals who have benefited from outstanding care during his tenure.”

According to a university web page, Caligiuri has designed and conducted many clinical studies looking at leukemia and lymphoma, and has more than 400 publications, abstracts and review articles on immunology or leukemia. More than 100 students have received over 70 awards for work done in Caligiuri’s lab since 1990, the website says.

Caligiuri also serves as president of the American Association for Cancer Research, a professional organization of more than 37,000 members seeking to advance cancer research.

His resignation comes on the heels of the medical center’s loss in September of Dr. Ali Rezai, a leading neuroscientist who took a post at West Virginia University and its WVU Medicine health system.

Ohio State also recently announced it is launching a nationwide search for a chancellor who will oversee Wexner Medical Center and the university’s entire health sciences enterprise.

The position will be similar to that of the former CEO position held by Dr. Sheldon Retchin until he resigned in May after more than 40 physicians, in a series of complaints, expressed concerns about leadership at Wexner.

The chancellor position will have a broader scope meant to reflect the size and complexity of Ohio State’s health sciences enterprise, Drake told The Dispatch earlier this month.
Despite the tumult, the medical center had its strongest financial year ever last fiscal year, with $302 million in excess revenue after expenses, and is off to a successful start so far this fiscal year.

*Dispatch Reporter Jennifer Smola contributed to this story.* jviviano@dispatch.com @JoAnneViviano
Dr. Michael Caligiuri spoke to a crowd Thursday night during a Pelotonia fundraiser. This week, he announced his resignatio
as CEO of The James at Ohio State’s Wexner Medical Center. [ERIC ALBRECHT/DISPATCH]

The resignation of Dr. Michael Caligiuri as chief executive officer of Ohio State University’s cancer center is the latest in a handful of high-level departures from the university as it works toward a unified vision for its medical center.

Ohio State President Dr. Michael V. Drake announced Caligiuri’s resignation in a message to faculty and staff at the Wexner Medical Center on Wednesday.

No reason was given for the resignation.

Caligiuri, 61, will return to his tenured faculty position and will serve in a new role as special adviser to the president through the remainder of the year, Drake’s announcement said.

Caligiuri, who has not responded to Dispatch requests for an interview, declined to discuss his resignation with a reporter during his appearance Thursday night at a Pelotonia fundraising announcement at the Express Live! bar in the Arena District.
He received a rock-star-like ovation from the more than 400 people in attendance when he took the stage.

“...more often,” Caligiuri quipped. He noted that several people had approached him and asked, “Are you OK?”

“I’m great. Now I want to tell you why,” Caligiuri said.

Caligiuri said the Arthur G. James Cancer Hospital has become the third-largest cancer hospital in America. He said that 99 percent of the beds are filled with a waiting list and the hospital recently received a 100 percent rating from the National Cancer Institute.

“It’s a really good time, a fabulous time for me to turn the page and recharge and refresh,” Caligiuri said.

Miguel Perez, vice president and a spokesman for Pelotonia, said Caligiuri “has been a pivotal force” behind the nonprofit’s fundraising bicycle ride since the beginning, helping to form the partnership between the nonprofit and The James and said Caligiuri has ridden in the event.

“He’s inspired this whole movement, and we know he’ll continue to be involved.”

A transition team has been put in place and will work toward finding a new leader for Ohio State’s Comprehensive Cancer Center and Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. But new leadership at The James will have a different reporting structure, university spokesman Chris Davey said Thursday.

Caligiuri reported directly to the university president, which is fairly uncommon for cancer centers, Davey said. The new leader of The James will instead report to a new chancellor of Ohio State’s medical center, a position that the university is currently working to fill.

“We’re focused on continuing to work together as a team where everyone is unified with a common vision for the medical center,” Davey said.

Caligiuri’s departure follows that of Dr. Sheldon Retchin, who stepped down as CEO of the Wexner Medical Center in May after a group of physicians and professors signed a letter of no-confidence in his leadership. The university has maintained that allegations raised against him in those letters were untrue, but some of the complaints surrounded the medical center’s relationship with the cancer program.

In the first of a small series of letters, a group of 25 employees — all cancer doctors and researchers — cited a specific concern with Retchin and his team asserting their leadership over The James.

“Placing any aspect of the cancer program under Dr. Retchin and/or his team would be a fatal blow to the continued success of the OSUCCC-James and would put at risk the economic benefits … and the collaborative environment that the OSUCCC-James has developed over the last 20 years ...”

Caligiuri steps down amid increasing tensions at the medical center, much of which revolve around the cancer center’s independence, detailed in the December issue of Columbus Monthly.

Spats over The James’ independence have broken out from time to time since its founding, Columbus Monthly reported. Those haven’t publicly involved Caligiuri, but he has survived them and remained a constant in medical center leadership, outlasting many others.

Drake announced earlier this month that the university is launching a nationwide search for a chancellor who will replace Retchin and oversee the medical center and the university’s entire health-sciences system. Details
of the new position are still being developed, but the new role is intended to “reflect the size and complexity of the health-sciences enterprise,” Drake told The Dispatch.

Since the announcement, speculation has swirled about whether the cancer program would fall under the new chancellor’s purview. The university confirmed Thursday that it would.

“The state of the Wexner Medical Center has never been better,” said Davey, citing the medical center’s most successful fiscal year last year, high patient satisfaction scores and being named one of the best hospitals in the country for the 25th straight year.

“The way forward is to continue to organize and operate ourselves effectively and efficiently as one medical center, within one university, focused on one goal: the health and wellness of the people we serve,” he said.

Seeking independence and control isn’t uncommon within hospital systems, said J.B. Silvers, a professor of health finance at Case Western Reserve University, especially for a comprehensive cancer center, where a prospective payment system exemption, revenue, research funding and prestige are often in play.

“Everybody loves to build their own little fiefdom,” Silvers said. “Trying to manage it is like herding cats.”

Caligiuri’s and Retchin’s resignations were preceded by the September 2016 departure of Dr. Ali Rezai, a leading neuroscientist who took a position with the health system at West Virginia University, where former Ohio State president E. Gordon Gee is president.

Some turnover at hospital systems is to be expected, Silvers said, given the high level of talent of the faculty and researchers. The important thing is to make sure the top talent isn’t leaving for the wrong reasons and that the university successfully manages such transitions, he said.

“I wish them good luck, because if you don’t do the transition right, it can be really messy and very damaging for the institution,” he said. “It’s an opportunity to change the focus and pull things together.”

jismola@dispatch.com jwoods@dispatch.com @jennsmola @Woodsnight
Two more Ohio State medical leaders leave for West Virginia University

By Jennifer Smola
The Columbus Dispatch
Posted Feb 6, 2018 at 5:22 PM
Updated at 7:15 AM

Dr. John Campo and Rhonda Campo are leaving Ohio State University's Wexner Medical Center, becoming the most recent in a string of leaders exiting Ohio State to follow former university president E. Gordon Gee to West Virginia University.

Dr. Campo has been at Ohio State since 2006, most recently serving as chairman of the university's Department of Psychiatry and Behavioral Health at the Wexner Medical Center.

He will serve as an assistant dean of behavioral health and wellness, chief behavioral wellness officer and professor with the West Virginia University School of Medicine at the Rockefeller Neuroscience Institute in Morgantown, West Virginia.

His wife, Rhonda, who is listed as Rhonda Stolec-Campo on Ohio State's website, is associate executive director of the James Cancer Hospital at Ohio State. She will serve as associate vice president of strategic development, commercialization and innovation at WVU's Rockefeller Neuroscience Institute.

Dr. Campo will be paid $430,000 a year at WVU; Rhonda Campo will get $275,000 annually. The two made at least $366,000 and $116,000, respectively, at Ohio State, according to 2015 salary information.

The Campos are at least the sixth and seventh doctors or executives since 2014 to leave Ohio State for positions with WVU's medical system.

Gee, as well as former Ohio State physicians Dr. Ali Rezaei and Dr. Clay Marsh, praised the addition of the Campos to WVU in the university's announcement Tuesday.

"I am always optimistic about West Virginia University and West Virginia," Gee said in a statement. "That optimism reaches its peak when we attract top talent from around the country and around the world. With the addition of John and Rhonda Campo to
the Rockefeller Neuroscience Institute, this is surely one of those great days. We are committed to building one of the best academic medical centers in the country, and having them join us puts us another step closer.”

Rezai, a leading neuroscientist, left Ohio State last year to serve as executive chairman and vice president of neurosciences for WVU medicine. Marsh, former chief innovation officer at the Wexner Medical Center, left in 2015 to become WVU’s vice president and executive dean for health sciences.

Other recent Ohio State departures include Richard Goldberg, former physician in chief at the James Cancer Hospital; J. Philip Saul, former associate dean for children’s and transitional health at OSU as well as former chairman of pediatrics at Nationwide Children’s Hospital; and Stephen Hoffman, former vice chairman for clinical affairs at OSU’s Department of Internal Medicine.

jsmola@dispatch.com

@jennsmola

SIGN UP FOR DAILY E-MAIL
Wake up to the day’s top news, delivered to your inbox

MOST POPULAR STORIES
Another Ohio State medical center executive moving on

By Jennifer Smola
The Columbus Dispatch
Posted Feb 8, 2018 at 3:48 PM
Updated Feb 8, 2018 at 5:28 PM

Another executive is leaving Ohio State University, the most recent in a number of high-level departures from the Wexner Medical Center and the university's cancer center.

Jeff Walker, senior executive director for administration at the Ohio State Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, has accepted a position at City of Hope National Medical Center in Duarte, California. There, Walker will serve as senior vice president for transformation and development. He will start his new job late this month, according to an internal memo sent to the James staff announcing his departure.

Walker was the first chief operating officer and senior executive director of administration for Ohio State's cancer program, according to the memo, signed by William Farrar, interim chief executive of the James, and Raphael Polluck, director of Ohio State's Comprehensive Cancer Center.

"With Jeff's leadership, the James has had record performance nationally, both from the financial and patient-satisfaction perspectives," the memo said. "It is largely because of his contributions that Ohio State has one of the nation's most elite cancer programs."

At City of Hope, Walker will join Dr. Michael Caligiuri, former chief executive of the James. Caligiuri was appointed president and physician-in-chief at City of Hope in November.

Kris Kipp, executive director of patient services and chief nursing officer, will assume Walker's role going forward. Nancy Single, director of clinical research operations, and Christine Scarcello, director of research operations, will co-lead the cancer center's administration, the memo said.

Walker made nearly $558,000 in his role at Ohio State, according to recent salary information. Salaries for Kipp, Single and Scarcello, were not immediately available.

Other recent medical departures at Ohio State include Dr. John Campo and Rhonda Campo, who have accepted positions at West Virginia University's medical center, WVU announced this week. Randy Nelson, chairman of the department of neuroscience, and Courtney DeVries, professor of neuroscience, also left Ohio State for WVU late last month. A number of other medical leaders or executives had left Ohio State in previous months.

jsmola@dispatch.com

@jennsmola

SIGN UP FOR DAILY E-MAIL
Wake up to the day's top news, delivered to your inbox
Yow Cancer Fund backs OSU research

By JoAnne Viviano The Columbus Dispatch

Ohio State University researchers studying uterine cancer received a boost on Wednesday with a $100,000 gift from the Kay Yow Cancer Fund, named after the late North Carolina State women’s basketball coach who wished for the organization to support cancer research in every Final Four host city.

The money will help fund a project at Ohio State’s James Cancer Hospital and Comprehensive Cancer Center that seeks to help doctors create targeted treatments for women with the disease.

The grant was publicly announced at Nationwide Arena, which is hosting the NCAA women’s Final Four games on Friday and the championship game on Sunday.

“We donate this on behalf of all women’s basketball coaches, players and fans across the country,” Stephanie Glance, the fund’s chief executive officer, told The Dispatch by phone. “It is something that women’s basketball can do through the Kay Yow Cancer Fund in the fight against all women’s cancers that far exceeds wins and losses on the court.”

The grant will fund research into the uterine cancer that forms in the organ’s lining, or endometrium. It is the most common gynecological cancer in the United States, with about 60,000 women diagnosed annually and about 11,000 dying each year. Though an increasing number of women are diagnosed and an increasing number die each year, little research funds are devoted to the disease, said Dr. David Cohn, director of gynecologic oncology at the James.

The grant will allow researchers to review the molecular, or genetic, profiles of tumors from more than 700 women who have had endometrial cancer to determine which are linked to recurrence or death and which are not, said Paul Goodfellow, professor of obstetrics and gynecology at the James and the Cancer Center.

Oncologists will be able to apply the findings to other patients to determine whether they should undergo chemotherapy and/or radiation or can avoid those toxic and painful treatments, Cohn said. The project also will drive research into new therapies based on genetic profiles, Goodfellow said.

Glance said the Cancer Fund gathers research proposals in each Final Four city then works with an advisory committee of top oncologists at the V Foundation for Cancer Research, a charity founded by ESPN and former North Carolina State men’s basketball coach Jim Valvano. The fund’s board chooses recipients based on the committee’s recommendations.

Yow died in 2009 at age 66 after a 22-year, on-again, off-again battle with breast cancer. She had founded the Cancer Fund before her death to help fight all cancers affecting women.

Yow coached basketball for 38 years, including 34 seasons at North Carolina State University. Since her death, the Cancer Fund has given $1.15 million in Final Four cities, part of the $5.63 million total it has donated since its inception in 2007.
She was a founding member of the Women’s Basketball Coaches Association, won a 1988 Olympic gold medal as a coach, and is in numerous halls of fame, including the Naismith Basketball Hall of Fame. She received the inaugural Jimmy V ESPY for Perseverance in 2007 and was named national Coach of the Year eight times.

Yow went to 20 NCAA tournaments and made 11 trips to the Sweet 16, and a trip to the Elite Eight and the Final Four in 1998. jviviano@dispatch.com @JoAnneViviano
$102M for cancer fight

Pelotonia’s 5-year pledge helps OSU’s new Institute of Immuno-Oncology

By JoAnne Viviano
The Columbus Dispatch

Dr. Zihai Li, center, meets with some of his team members in the Pelotonia Institute of Immuno-Oncology on Thursday. They are, from left, Donna Bucci, Nojoon Song, Kelly Danner and Elizabeth Robins. [ERIC ALBRECHT/DISPATCH]

The Ohio State University Comprehensive Cancer Center will receive more than $102 million from Pelotonia, more than half of the total collected in the 11-year-history of the fundraising bike ride, the university announced Friday.

The funds will come over the next five years, with $65 million going to a newly launched Pelotonia Institute of Immuno-Oncology and the rest supporting ongoing initiatives. The pledge represents the largest gift made to the university’s cancer program.
Dr. Zihai Li, founding director of Ohio State University's new Pelotonia Institute of Immuno-Oncology, arrived in Columbus in April from the Medical University of South Carolina, and his team followed this month. Over the next five years, he hopes to recruit 32 additional research investigators and their teams.

[ERIC ALBRECHT/DISPATCH]

Ulman, Pelotonia's president and CEO, who credited those initial riders for creating and leading the movement over the past decade.

Since its inception, Pelotonia has raised more than $194 million for the Cancer Center, which includes the Arthur G. James Cancer Hospital and the Richard J. Solove Research Institute. This year's event, with an opening ceremony on Aug. 2 and riding on Aug. 3-4, has 7,360 registered riders and has raised more than $10 million so far.

Dr. Zihai Li, founding director of the new institute, said federal dollars for cancer research remain stagnant, and the support from Pelotonia is critical to jump-start research at the institute. The Cancer Center is committing an additional $35 million to the endeavor.

Li referenced the use of a vaccine to eradicate smallpox, which once killed hundreds of thousands of people a year, to demonstrate the power of the immune system.

"The defense mechanism, can we make it better? Can we boost immune function?" Li said. "In people who have cancer, it means the immune system failed. Can we rewire it?"

Li said there has been success with a therapy that uses molecular switches to reactivate certain white blood cells, called T-cells, that become exhausted and fail in their job to attack cancer cells.

Although the therapy has been effective in treating several cancers, including those of the lung, bladder, liver, kidney and skin, it has not shown success against others, including brain tumors and ovarian and pancreatic cancers.
"We want this to be useful and effective for every patient of every cancer. We’re not there yet,” he said.

Li arrived in Columbus in April from the Medical University of South Carolina, where he was chair of microbiology and immunology and a co-leader of the Hollings Cancer Center immunology program. His team followed this month. Over the next five years, he hopes to recruit 32 additional research investigators and their teams.

"Once that’s done, there will be hundreds of people working in this area,” he said. “That will move the needle.”

Research dollars, especially private donations that allow scientists leeway, are crucial to developing cutting-edge therapies, said Dr. Robyn Stacy-Humphries, a North Carolina radiologist who traveled to the James in 2016 to have her lymphoma treated with CAR-T therapy as part of a clinical trial.

Now FDA-approved for certain blood cancers, the therapy takes T-cells from a patient’s blood, genetically alters them to target molecules on cancer cells, and re-injects them.

Stacy-Humphries said therapies like hers and immunotherapies allow people to return to daily activities more quickly and will, 20 years from now, make today’s use of chemotherapy seem medieval.

“With immunotherapy, people often are able to return to their lives and live their lives, whether it’s a wife and mother or an executive, they actually can return to being a functional human,” she said. “... That’s one reason it’s so remarkable; it’s tolerated so much better.”

Ulman said the Pelotonia pledge marks the first time the fundraiser has made a multi-year, forward-looking investment. He said the first portion of the pledge will be made later this year or early next year.

It’s powerful, he said, to be able to make the pledge on behalf of the community, which will see its impact in the foreseeable future.

“Tens of thousands of people have ridden, tens of thousands of people have volunteered, and hundreds of thousands have gone to a bake sale or made a donation or bought a T-shirt,” Ulman said. “... This is a massive community that understands the perils of this disease and wants to do something about it.”

Li will add to the numbers this year as he rides in his first Pelotonia.

“I want to be part of the movement,” Li said. “... Actually it’s one of the reasons I came here to Columbus. I feel people here are amazing and so caring and believe in what, collectively, we can do.”

jviviano@dispatch.com @JoAnneViviano
Show of support

Pelotonia still going strong, fueled by so many people’s stories

By Ben Deeter

The Columbus Dispatch

Ellie Brasky, 9, was with her younger brother to cheer on their dad, Ted, as he headed toward the Pelotonia finish line at Kenyon College in Gambier on Saturday. [KYLE ROBERTSON/DISPATCH]
Riders make their way to the starting line for the 11th Pelotonia at North Bank Park in the Arena District Saturday morning. [KYLE ROBERTSON/DISPATCH]

As the sun began rising over the horizon Saturday morning, hundreds of riders in this year’s Pelotonia left New Albany’s Bob Evans headquarters behind them as they set off on their ride.

They were joined by thousands of other riders kicking off their own rides at McFerson Commons in the Arena District and Pickerington North High School in Pickerington. Another group of
Kevin Vorhees’ shirt was covered in names as he prepared to start on his Pelotonia ride. Many participants honor loved ones who have battled cancer, or donors, by displaying their names during the ride. [KYLE ROBERTSON/DISPATCH]

Zack Shevchenko, of the Hamilton Parker Company team, waves after crossing the start for the 45-mile Pelotonia route in Pickerington. [MADDIE SCHROEDER/FOR THE DISPATCH]

Riders will start Sunday at Denison University in Granville for a new 35-mile route.

In total, the ride drew 7,494 riders. The first Pelotonia 11 years ago included 2,265.

The organization’s fundraising reflects this growth. This year, Pelotonia raised more than $13.5 million, bringing the total raised across all 11 rides to more than $197 million. All of the money goes toward cancer research through a partnership with Ohio State University’s James Cancer Hospital.

The organization asked its riders and supporters, “What’s your arrow?” ahead of the ride, referencing the arrow that is used as a symbol for Pelotonia, and the many reasons that people come out to ride, volunteer or support those participating.

Sheri Lytle’s “arrow” is her own experience with breast cancer. She was diagnosed in 2016 and is a three-year survivor.

Lytle joined people on the sideline in Granville to cheer on her husband, Matt, who rode for the first time this year. She brought a collection of signs with a variety of messages to help riders along.

“Go Random Stranger!” one read. “It’s Just a Hill. Get Over It!” another said.

“It’s overwhelming to see all these people come together for such an amazing cause,” Lytle said. “So many people dedicate so much time and energy, and it’s not just the riders who come out for this ride. There’s just so much community involvement in it, and it’s really overwhelming to see it all.”

Pelotonia riders can choose ride lengths ranging from 25 miles in one day all the way up to 200 miles across two days. Each route has a minimum fundraising requirement for every rider, with the low end at $1,250 and the high end at $3,000.
John and Lisa Barrett of Wapakoneta stood in the shade at the edge of the Bob Evans headquarters holding a large letter “Z” and “H” in support of their son, Zach, and his wife, Heather, who won Miss Ohio in 2013. The two rode with the corporate team from L Brands in their second Pelotonia ride.

The Barretts had pasted the letters together using pictures of Zach and Heather. They hoped Zach would not repeat the mishap from his first ride last year.

“Zach got a flat tire last year at the last couple of miles,” Lisa Barrett said, laughing. “So they got stuck in the woods for like an hour.”

It’s not just flat tires that can set riders back. The routes themselves often have long, steep inclines that require riders to either shift gears and pedal faster or hop off their bikes and walk for a few minutes.

“I’m tired, but it’s for a good cause,” said Shireen Woodiga, a first-time rider originally from Malaysia who now lives in Columbus, as she walked up a hill in Knox County. “For me, it’s not personal. I don’t have someone close who has had cancer, but it just felt like it’s the right thing to do. So, I guess you could say I ride for those who have no one to ride for them.”

The riders sport bright colors, company logos and the names of those they ride for on their outfits. Some take it a step further, writing the names on their bodies.

Thomas Davis, of Centerburg, rode for his late brother, uncle and other family members who fought cancer. He had their names, along with those of donors to his ride, written on his arms and legs in black marker.

As Davis pulled through the finishing stretch, his three children rushed out to greet him with handmade pictures, nearly getting hit by oncoming bikes in the process.

“I always wanted to do it for maybe seven years — I’d always seen the people riding or I saw the magnets on the cars,” Davis said after finishing his 55-mile ride in Gambier.

“But on my brother’s passing, I had that conviction to do something kind of big.” bdeeter@dispatch.com @BenDeeter
COLUMBUS, Ohio – After serving as the interim leader for almost two years, Dr. William Farrar will become CEO of The Ohio State University Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (The James), pending approval by The Ohio State University Board of Trustees. In this role, he will report to Dr. Hal Paz, executive vice president and chancellor for health affairs at Ohio State and CEO of The Ohio State University Wexner Medical Center. Farrar is a surgical oncologist and has a long, successful history with Ohio State, serving on The James medical staff since it opened in July 1990. The late Dr. Arthur G. James, for whom the hospital is named, mentored and later worked alongside Farrar.

"Dr. Farrar's experience with this fine institution makes him ideally suited to lead The James toward even greater heights. I look forward to working together to advance research-based cancer care," Paz said.

In addition to being clinically active, Farrar has had many Ohio State leadership positions. Currently, he holds the Dr. Arthur G. and Mildred C. James – Richard J. Solove Chair in Surgical Oncology, is director of
the Stefanie Spielman Comprehensive Breast Center and is a member of the Molecular Carcinogenesis and Chemoprevention Research Program in The Ohio State University Comprehensive Cancer Center. He also directed the Division of Surgical Oncology for 28 years and was director of medical affairs at The James for 22 years.

“We’ve built a tremendous cancer hospital and research enterprise in Columbus, and I am honored to continue to do my part to help lead our clinical enterprise as we embrace a very hopeful new area of genomic-driven care and immuno-oncology approaches that allow us to offer personalized, more effective treatment options to our patients,” Farrar said.

On a national level, Farrar serves as president of the U.S. National Committee for International Union Against Cancer. He’s also principal investigator for the National Surgical Adjuvant Breast and Bowel Project Clinical Trial group at Ohio State. He has served on numerous national committees including the Training Directions Committee for the Society of Surgical Oncology, the Joint Council for Approval of Advanced Training in Head and Neck Oncology Surgery, the American College of Surgeons Committee on Cancer and the American Association of Clinical Endocrinologists.

Farrar has published more than 100 cancer research journal articles along with several book chapters and scientific abstracts. He served for many years on the editorial boards for the Journal of Surgical Oncology, the Annals of Surgical Oncology and the Southwest Oncology Group.

His national honors include 18 appearances on the Castle Connolly list of “America’s Top Doctors” and 16 appearances on the “Best Doctors in America” list, as well as being rated in the top 10% of physicians in the nation for patient satisfaction in 2017.

###
Doctor gets grant for cancer research

By Megan Henry

The Columbus Dispatch

The Susan G. Komen foundation has awarded a research grant to a breast radiation oncologist at the Ohio State University Comprehensive Cancer Center, home to the Arthur G. James Cancer Hospital.

Dr. Julia White received a $200,000 Komen grant to research how to better treat malignant breast tumors.

In September, Susan G. Komen announced $26 million in funding for new research projects focused on metastatic breast cancer, to develop new treatments and differences in breast cancer outcomes. Komen awarded 60 grants and White was the only doctor in Ohio to receive a Komen grant.

“Breast cancer does not affect everyone equally and with the grants we’re funding this year, we’re moving closer to new therapies for aggressive forms of cancer, understanding why treatment doesn’t work in some patients and making sure everyone has access to the care they need,” Paula Schneider, Susan G. Komen’s president and CEO, said in an emailed statement.

With the grant money, White plans to see whether radiation of tumors before surgery could help the immune response fight triple negative breast cancer, an aggressive type of breast cancer. The immune response is how a body defends itself against foreign bacteria, viruses and substances.

Triple negative breast cancer is a type of breast cancer that does not have any of the receptors that are commonly found in breast cancer such as estrogen and progesterone, making it harder to treat. It’s typically treated through a lumpectomy, mastectomy, radiation or chemotherapy. Triple negative occurs in about 10% to 20% of all breast cancers, and it is most likely to affect younger people, African Americans and those with a family history of breast cancer.

Typically, radiation comes after surgery and chemotherapy. White’s goal is to hit the breast cancer with highly focused bursts of radiation three times in one week and then let the patient go through her normal treatment with surgery, chemotherapy or targeted radiation. The goal is to give the tumor just enough radiation to prime the immune system to recognize cancer and therefore improve the effectiveness of primary treatments. White hopes to start the trial in January and plans to enroll 18 patients.

“By developing a means for giving a little bit of radiation right on the tumor, right at the beginning of treatment, we’re looking to see how the cancer reacts,” White said. “It gives us this very powerful way to say we can then manipulate how the tumor reacts to radiation to see if we can use it to enhance its response to immunotherapies.”

Immunotherapy is a type of cancer treatment that helps your immune system fight cancer. Melanoma, a skin cancer, is the cancer most commonly treated with immunotherapy.

“One of the most burning questions in cancer right now is immunotherapy,” White said. “Can we use radiation to charge up the immune system?”
Breast cancer is the most common cancer among women in the United States and Ohio, according to the Ohio 2016 Behavioral Risk Factor Surveillance System Annual Report. In 2016, 245,299 new cases of female breast cancer were reported and 41,487 women died of breast cancer in the United States, according to the federal Centers for Disease Control and Prevention in Atlanta. In Ohio that year, 9,648 new cases of female breast cancer were reported, and 1,711 women died of breast cancer.

“I think people forget how big of a deal (breast cancer) is,” said Julie McMahon, Susan G. Komen Columbus director of mission.

White has been a Komen Scholar since 2010. The Komen Scholars are an advisory group of 52 distinguished scholars and leaders in breast cancer research. She said she is looking forward to seeing the results of her study.

“It’s something that would be feasible, doable and not that expensive if it could enhance immune response,” White said. mhenry@dispatch.com @megankhenry
Ginnie Hough, left, was diagnosed with breast cancer in November 2016 and paired with Anne Saas, a six-year cancer survivor, through Ohio State’s H.O.P.E. program. The program matches cancer patients with survivors for guidance, friendship and more.

[JOSHUA A. BICKEL/DISPATCH]

When Ginnie Hough was diagnosed with breast cancer, her world shattered.

The mother of three thought she was going to die — that she had to prepare herself and her family for that inevitability.

"My wind was completely taken out of my sails," she said of her November 2016 diagnosis.
Hough, of New Albany, also wondered how she would manage her human resources career, for which she has a real passion, while undergoing various treatments. And she worried how she would communicate with her family about what she was feeling, both physically and mentally.

Then she met Anne Saas.

During Hough's second round of chemotherapy in early 2017, she read a pamphlet promoting the H.O.P.E. (Healing Others through Peer Experiences) Program at the Ohio State University Arthur G. James Cancer Hospital, where she was being treated.

Started in January of that year, the program connects cancer patients or caregivers to someone who has had a similar cancer experience, to offer support through treatment and beyond.

"I called and told them I really need this — that I'm a mess," Hough said. "I need to talk to someone."

Saas, a six-year breast cancer survivor, became that lifeline for Hough.

Hough cried as she recalled her first meeting with Saas in which the two women swapped stories about their cancers, their love for their careers and, coincidentally, how they both have a son named Austin.

"My reaction was 'here is somebody I can ask anything of,'" Hough said. "It was a place where I could ask questions that I maybe didn't want to ask my family. They get burnt out. They're driving you to doctors' appointments, trying to listen to the oncologist."

Saas, 57, of Lewis Center, became a guide for the H.O.P.E. program. Her treatment had been successful and she wanted to turn her cancer journey into something positive and give back.

Plus, she knew how useful something like this could have been when she went through her own surgery, chemotherapy and radiation in 2013.

"My husband is more emotional than me ... He knew I was feeling sick, but I wanted to be strong for him," Saas said. "It would've been nice to have someone to talk to about all of this."

It's exactly what the James had been hearing from patients prior to the program's inception, said Julie DeBord, who manages H.O.P.E.

She said those diagnosed with cancer and their caregivers both yearn for this type of connection and well, hope, that there is life after cancer.

"It's a really powerful moment when a cancer patient has the opportunity to talk to someone who gets it and listens without judgment," DeBord said. "A cancer diagnosis can impact so many facets of life."

Other agencies and institutions across the nation have similar types of peer-support programs, DeBord said, and the James wanted to do the same.

The American Cancer Society, for example, has matched breast cancer patients with trained volunteers through its Reach to Recovery program for more than five decades, said Celeste Lauer, a senior manager for the Ohio and West Virginia region of the nonprofit group.

Providing training for volunteer guides was important to the James, DeBord said, as was serving all types of cancer patients. Mentors must be one year post-treatment, and go through educational sessions on ways
to connect, how to establish boundaries and how to promote self-care. They're asked to commit six months to each partner for whom they are paired, but many continue strong relationships after that commitment ends.

Each pairing finds the best ways and frequency to communicate, DeBord said, and the program attempts to match people with similar disease types, treatment plans, family life, career, age and gender.

So far, they've matched more than 100 pairs, she said.

Yavonne McGarry has known Liz Magee for only four months, but she can't emphasize enough how much the Bexley mother of three has helped her as she continues hormone treatment for the breast cancer she was diagnosed with in summer 2018.

McGarry, who also is a mother of three, has struggled with the psychological battles of cancer as much, if not more, than the physical pains.

"The cancer journey — I was surprised by how psychological it was," said McGarry, 45, of Upper Arlington. "I'd think, 'this is my life now.' The acceptance, it's almost like the stages of grief. Then the medical menopause was when things got really hard. It messes with your mood."

Magee has assured her it's all normal, instead of offering unsolicited advice, which McGarry said can be the worst thing a friend or family member can do when trying to be supportive.

Magee, also 45 (the two women have a variety of similarities, including both having husbands named Andy), said she strives to be available however she's needed.

"I like to lead with, 'Any question is OK. You can ask me any question on the table' — that ranges from how to manage a diagnosis with family or work to any fear that they might happen to have," Magee said.

Over the phone and via text, the two women have covered every topic from hot flashes and hormone therapy to their own mortality and dealing with teenagers. They had planned to meet in person for the first time earlier this month.

"I'd done a couple of support groups, but this one-on-one attention is no match for (those)," McGarry said. "I know she's there for me."

That sentiment was echoed by Hough, who still goes to lunch with Saas once a month. They've even gone hiking with their husbands at Hocking Hills State Park after Hough began feeling better.

Though they might compare bone-density scan results during their lunches, they also talk about family, work and most importantly, hopes for the future.

"I don't want to live my life in fear and you can get stuck in that," Hough said. "It's nice to have someone pull you out of that trap." award@dispatch.com @AllisonAWard